Published in BMJ on August 18, 2007
Medication adherence and persistence in severe obstructive sleep apnea. Sleep (2009) 1.05
Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet (2005) 17.08
Comparison of therapeutic and subtherapeutic nasal continuous positive airway pressure for obstructive sleep apnoea: a randomised prospective parallel trial. Lancet (1999) 6.37
Those confounded vitamins: what can we learn from the differences between observational versus randomised trial evidence? Lancet (2004) 6.37
Ambulatory blood pressure after therapeutic and subtherapeutic nasal continuous positive airway pressure for obstructive sleep apnoea: a randomised parallel trial. Lancet (2002) 4.86
Effect of CPAP on insulin resistance and HbA1c in men with obstructive sleep apnoea and type 2 diabetes. Thorax (2007) 3.07
Controlled trial of continuous positive airway pressure in obstructive sleep apnea and heart failure. Am J Respir Crit Care Med (2003) 2.96
Influence of obstructive sleep apnea on mortality in patients with heart failure. J Am Coll Cardiol (2007) 2.81
Sleep. 1: Obstructive sleep apnoea/hypopnoea syndrome: definitions, epidemiology, and natural history. Thorax (2004) 2.62
Prevalence of obstructive sleep apnoea in men with type 2 diabetes. Thorax (2006) 2.46
Obstructive sleep apnea syndrome affects left ventricular diastolic function: effects of nasal continuous positive airway pressure in men. Circulation (2005) 2.22
Neck circumference and other clinical features in the diagnosis of the obstructive sleep apnoea syndrome. Thorax (1992) 2.21
Methods of estimation of visceral fat: advantages of ultrasonography. Obes Res (2003) 1.46
Does arousal frequency predict daytime function? Eur Respir J (1998) 1.41
Clinical outcomes and cost-effectiveness of continuous positive airway pressure to manage obstructive sleep apnea in patients with type 2 diabetes in the U.K. Diabetes Care (2014) 2.04
Cost-effectiveness of oral appliances in the treatment of obstructive sleep apnoea-hypopnoea. Sleep Breath (2009) 0.90
Effect of ondansetron on moderate obstructive sleep apnoea, a single night, placebo-controlled trial. J Sleep Res (2003) 0.83
Tobacco industry lobbyists and their health-care clients. Lancet (2013) 0.82
Con: Sleep apnea does not cause cardiovascular disease. Am J Respir Crit Care Med (2004) 0.81
SleepAp: an automated obstructive sleep apnoea screening application for smartphones. IEEE J Biomed Health Inform (2015) 0.79
Elevated levels of endothelial cell-derived microparticles following short-term withdrawal of continuous positive airway pressure in patients with obstructive sleep apnea: data from a randomized controlled trial. Respiration (2012) 0.79
Atherosclerosis and arterial stiffness in obstructive sleep apnea--a cardiovascular magnetic resonance study. Atherosclerosis (2012) 0.79
Brain natriuretic peptide is unchanged after 4 weeks of continuous positive airway pressure therapy. J Sleep Res (2006) 0.77
Platelet function (measured by Platelet Function Analyser--100) and obstructive sleep apnoea. J Sleep Res (2005) 0.76
European guidelines for accreditation of sleep medicine Centres. J Sleep Res (2007) 0.75
Driving and obstructive sleep apnoea. Thorax (2008) 0.75
Protocol for diaphragm pacing in patients with respiratory muscle weakness due to motor neurone disease (DiPALS): a randomised controlled trial. BMC Neurol (2012) 0.75
Diabetes in obstructive sleep apnea. Am J Respir Crit Care Med (2010) 0.75
The role of the dentist in sleep disorders. Dent Update (2011) 0.75
Indices of hypoxic stress in sleep apnea. Am J Respir Crit Care Med (2009) 0.75
Effect of continuous positive airway pressure treatment for obstructive sleep apnoea on visual processing of degraded words. Respiration (2013) 0.75
Withdrawal of Continuous Positive Airway Pressure Therapy for 2 Weeks in Obstructive Sleep Apnoea Patients Results in Increased Circulating Platelet and Leucocyte-Derived Microvesicles. Respiration (2016) 0.75